Search results

• 2022

  Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

  Vicencio Bustamante, J., Evans, R., Green, R., An, Z., Deng, J., Treacy, C., Mustapha, R., Monypenny of Pitmilly, J., Costoya , C., Lawler, K., Ng, K., Desouza, K., Coban, O., Gomez, V., Clancy, J., Chen, S., Chalk, A., Wong, F., Gordon, P. & Savage, C. & 20 others, Gomes, C., Pan, T., Alfano, G., Dolcetti, L., Chan, J. N. E., Florez-Borja , F., Barber, P., Weitsman, G., Sosnowska, D., Capone, E., Iacobelli, S., Hochhauser, D., Hartley, J., Parsons, M., Arnold, J., Ameer-Beg, S., Quezada, S. A., Yarden, Y., Sala, G. & Ng, T., 28 Mar 2022, In: Cell Death & Disease. 13, 3, 274 .

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Elimination 100%
  • Apoptosis 50%
  • Chemotherapy 50%
  15 Citations (Scopus)

  157 Downloads (Pure)